9976 in, seems a good time short bet to me?
11K? |
Was expecting they would be taking over LumiraDx LMDX after partnership deal
hxxps://www.pharmashots.com/16262/lumiradx-collaborates-with-astrazeneca-and-everton-to-establish
Turns out it may be Roche RHHBY |
AZN now well below the 200 & 50 day moving average, the 200 day MA is approx 11000 area so this is a steal IMO with all the future developments in phase 11 & 111 trials. One aspect I also like is the fact AZN do not stand still and get complacent the company is always striving to get bigger and make regular acquisitions.
AZN was my very first stock I purchased when I was a complete newbie back in 2001 and I paid £17.50 a share back then, look at the growth of this immense stock of which I'm sure will get to £130 by the end of 2024 IMO, AZN was in my portfolio in 2001 at 1750 and still are and has been my best performing stock, just wished I'd have bought more and left them alone re-investing the dividends along the way.
Strong buy IMO. |
JPMorgan cuts AstraZeneca price target to 13,000 (14,000) pence - 'overweight' |
I have placed a limit order to buy at 95. I may pull it in favour of something paying a better dividend. there is plenty to chose from at present. The important thing in this market is not to chase. Let the price come to us. |
Sharecast market report..
"....Pharmaceutical giant AstraZeneca was off 1.73% after a broker note from Jefferies, which lowered its price target on the shares from 13,000p to 12,500p."
edit:
AstraZeneca sank after the City broker Jefferies stressed it needed to provide more clarity on its forecasts and cut its target price to 12500p from 13000p.
DMail market report |
One week on and it's really struggling again to hold £100 level. |
Questor tip 'Buy'
'Elephants don’t gallop – except for AstraZeneca'
Questor share tip: the company’s growth rate and valuation suggest further capital gains are ahead |
PER still looks very toppy, a lot of scope for disappointment there. |
Struggling to keep above £100 |
Greg B. Yes. They will divest China but whether that is a sale or separate listing, I don't know.
AZ China is 15% of AZ TO so its relevant. |
Fading already- maybe 2024 will be a better year. I'm sure part of the problem is that the incremental $$$$ is going into Eli Lilly and Novo Nordisk so Astra and others are being ignored |
Some good news...
In London’s FTSE 100, AstraZeneca rose 1.5%.
The pharmaceutical firm said its Truqap treatment for patients with advanced hormone receptor positive breast cancer, in combination with Faslodex, has been approved by the US Food & Drug Administration.
This follows the results from its CapItello-291 phase 3 trial published earlier this year, which showed reduced risk of disease progression or death by 50% compared to Faslodex alone. |
Do you have any more up to date info? |
I don't own AZ so have no interest.
hxxps://www.fiercepharma.com/pharma/misinformation-astrazenecas-china-head-refutes-spinoff-report
Not sure how a sale would effect the share price, be it a sale or standalone listing out of HK? One would assume this would be positive. |
A failure is a failure, simples! |
Blackhorse23 filtered. |
Could certainly do with some good news here. Hitting the 2023 lows now 😳 |
Money moving to APH , excellent healthcare dividend company |
WRT reaction, smallpox jab had 1 in 100K reactions, in a group of Royal Navy men.
Mr Watkins, Welsh, was found to have a hole in his heart.
Mr Evershed was found to have bowel cancer.
In both cases, 19yrs of age.
Both of these issues are recorded at the Journal. |
About time all the directors took their companies jabs and left to rot in jail |
£100 chart support about to go..... £97 next stop. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
